Candel Therapeutics IncNASDAQ:CADL
- LAST PRICE6.3000
- TODAY'S CHANGE (%)0.1000 (1.6129%)
- Bid / Lots6.3300/ 1
- Ask / Lots6.8400/ 5
- Open / Previous Close6.2000 / 6.2000
- Day Range
- 52 Week Range
- Volume593,332
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CADL |
|---|---|---|
| 09:32 ET | 22725 | 6.2 |
| 09:34 ET | 1882 | 6.12 |
| 09:36 ET | 1830 | 6.05 |
| 09:38 ET | 3380 | 6.035 |
| 09:39 ET | 599 | 6.025 |
| 09:41 ET | 2376 | 6.025 |
| 09:43 ET | 100 | 6.01 |
| 09:45 ET | 1750 | 6.02 |
| 09:48 ET | 1507 | 5.9 |
| 09:50 ET | 8598 | 5.92 |
| 09:52 ET | 7140 | 5.895 |
| 09:54 ET | 154 | 5.89 |
| 09:56 ET | 3403 | 5.97 |
| 09:57 ET | 5813 | 6.005 |
| 09:59 ET | 300 | 5.96 |
| 10:01 ET | 100 | 6 |
| 10:03 ET | 200 | 5.9999 |
| 10:06 ET | 614 | 6 |
| 10:08 ET | 3867 | 6.07 |
| 10:10 ET | 650 | 6.0599 |
| 10:12 ET | 200 | 6.03 |
| 10:14 ET | 650 | 6 |
| 10:15 ET | 640 | 6 |
| 10:17 ET | 900 | 6 |
| 10:19 ET | 1000 | 5.975 |
| 10:21 ET | 700 | 5.99 |
| 10:26 ET | 1149 | 5.9919 |
| 10:28 ET | 363 | 6.02 |
| 10:32 ET | 300 | 6.01 |
| 10:33 ET | 666 | 6 |
| 10:35 ET | 100 | 6.01 |
| 10:37 ET | 500 | 5.995 |
| 10:39 ET | 200 | 6 |
| 10:42 ET | 484 | 6.01 |
| 10:44 ET | 484 | 5.995 |
| 10:46 ET | 1667 | 5.98 |
| 10:50 ET | 265 | 5.955 |
| 10:51 ET | 1890 | 6.03 |
| 10:53 ET | 200 | 6.015 |
| 10:55 ET | 100 | 6.02 |
| 10:57 ET | 100 | 6.05 |
| 11:02 ET | 100 | 6.04 |
| 11:04 ET | 100 | 6.04 |
| 11:06 ET | 100 | 6.015 |
| 11:08 ET | 200 | 6.04 |
| 11:09 ET | 100 | 6.025 |
| 11:11 ET | 2175 | 6.02 |
| 11:15 ET | 600 | 6.04 |
| 11:22 ET | 700 | 6.045 |
| 11:24 ET | 800 | 6 |
| 11:26 ET | 200 | 6 |
| 11:27 ET | 300 | 6.02 |
| 11:29 ET | 600 | 6.01 |
| 11:31 ET | 714 | 5.97 |
| 11:33 ET | 300 | 5.98 |
| 11:36 ET | 800 | 5.97 |
| 11:38 ET | 400 | 5.94 |
| 11:40 ET | 2224 | 5.9105 |
| 11:42 ET | 300 | 5.93 |
| 11:44 ET | 200 | 5.92 |
| 11:45 ET | 200 | 5.92 |
| 11:47 ET | 200 | 5.9 |
| 11:49 ET | 652 | 5.93 |
| 11:51 ET | 6100 | 5.965 |
| 11:54 ET | 1904 | 5.98 |
| 11:56 ET | 1950 | 6 |
| 11:58 ET | 200 | 6 |
| 12:00 ET | 268 | 5.986 |
| 12:02 ET | 1977 | 6.06 |
| 12:03 ET | 650 | 6.1 |
| 12:07 ET | 100 | 6.1 |
| 12:12 ET | 200 | 6.1 |
| 12:14 ET | 1100 | 6.105 |
| 12:16 ET | 1595 | 6.1227 |
| 12:18 ET | 400 | 6.125 |
| 12:20 ET | 100 | 6.12 |
| 12:21 ET | 1109 | 6.16 |
| 12:25 ET | 800 | 6.16 |
| 12:27 ET | 5849 | 6.2 |
| 12:30 ET | 7017 | 6.24 |
| 12:32 ET | 200 | 6.23 |
| 12:34 ET | 7908 | 6.215 |
| 12:36 ET | 1808 | 6.2 |
| 12:38 ET | 100 | 6.1823 |
| 12:39 ET | 1550 | 6.169 |
| 12:41 ET | 1950 | 6.19 |
| 12:43 ET | 3023 | 6.205 |
| 12:45 ET | 200 | 6.2 |
| 12:48 ET | 500 | 6.2 |
| 12:50 ET | 500 | 6.205 |
| 12:52 ET | 4798 | 6.2 |
| 12:54 ET | 700 | 6.21 |
| 12:56 ET | 1180 | 6.22 |
| 12:57 ET | 1500 | 6.23 |
| 12:59 ET | 6248 | 6.245 |
| 01:01 ET | 100 | 6.245 |
| 01:06 ET | 950 | 6.24 |
| 01:08 ET | 450 | 6.24 |
| 01:10 ET | 4000 | 6.215 |
| 01:12 ET | 100 | 6.215 |
| 01:14 ET | 1800 | 6.225 |
| 01:15 ET | 100 | 6.24 |
| 01:17 ET | 300 | 6.225 |
| 01:21 ET | 3027 | 6.28 |
| 01:24 ET | 1723 | 6.29 |
| 01:26 ET | 1000 | 6.28 |
| 01:28 ET | 2450 | 6.27 |
| 01:30 ET | 700 | 6.27 |
| 01:32 ET | 1550 | 6.28 |
| 01:33 ET | 800 | 6.29 |
| 01:37 ET | 4447 | 6.33 |
| 01:42 ET | 6165 | 6.36 |
| 01:44 ET | 2150 | 6.31 |
| 01:46 ET | 1100 | 6.2865 |
| 01:48 ET | 100 | 6.26 |
| 01:50 ET | 750 | 6.245 |
| 01:51 ET | 2299 | 6.265 |
| 01:53 ET | 255 | 6.25 |
| 01:57 ET | 100 | 6.265 |
| 02:02 ET | 1588 | 6.295 |
| 02:06 ET | 100 | 6.3 |
| 02:08 ET | 6242 | 6.32 |
| 02:09 ET | 400 | 6.33 |
| 02:11 ET | 3550 | 6.3 |
| 02:13 ET | 300 | 6.3042 |
| 02:15 ET | 10106 | 6.355 |
| 02:18 ET | 2571 | 6.45 |
| 02:20 ET | 580 | 6.45 |
| 02:22 ET | 1813 | 6.43 |
| 02:24 ET | 4306 | 6.435 |
| 02:26 ET | 2204 | 6.43 |
| 02:27 ET | 1246 | 6.4111 |
| 02:29 ET | 350 | 6.405 |
| 02:31 ET | 16715 | 6.46 |
| 02:33 ET | 800 | 6.46 |
| 02:40 ET | 11179 | 6.46 |
| 02:42 ET | 600 | 6.46 |
| 02:44 ET | 4849 | 6.445 |
| 02:45 ET | 2155 | 6.46 |
| 02:47 ET | 100 | 6.475 |
| 02:49 ET | 3202 | 6.4899 |
| 02:51 ET | 42011 | 6.52 |
| 02:54 ET | 4155 | 6.53 |
| 02:56 ET | 3300 | 6.5 |
| 02:58 ET | 2067 | 6.51 |
| 03:00 ET | 3523 | 6.5 |
| 03:02 ET | 6968 | 6.505 |
| 03:03 ET | 5186 | 6.51 |
| 03:05 ET | 10369 | 6.51 |
| 03:07 ET | 8789 | 6.5 |
| 03:09 ET | 13622 | 6.5 |
| 03:12 ET | 1750 | 6.5 |
| 03:14 ET | 4118 | 6.47 |
| 03:16 ET | 1400 | 6.4648 |
| 03:18 ET | 400 | 6.455 |
| 03:20 ET | 1450 | 6.46 |
| 03:21 ET | 2734 | 6.49 |
| 03:23 ET | 900 | 6.4998 |
| 03:25 ET | 5420 | 6.52 |
| 03:27 ET | 19690 | 6.6 |
| 03:30 ET | 6789 | 6.575 |
| 03:32 ET | 4152 | 6.55 |
| 03:34 ET | 1365 | 6.54 |
| 03:36 ET | 2541 | 6.535 |
| 03:38 ET | 1035 | 6.54 |
| 03:39 ET | 4553 | 6.54 |
| 03:41 ET | 5975 | 6.46 |
| 03:43 ET | 500 | 6.46 |
| 03:45 ET | 661 | 6.45 |
| 03:48 ET | 841 | 6.45 |
| 03:50 ET | 1808 | 6.44 |
| 03:52 ET | 3802 | 6.43 |
| 03:54 ET | 3148 | 6.395 |
| 03:56 ET | 14088 | 6.38 |
| 03:57 ET | 6352 | 6.38 |
| 03:59 ET | 28698 | 6.3 |
Jun 18, 2024
Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference, from 8:00AM ET on Tuesday Jun 18, 2024 by Dow Jones
8:00AM ET on Tuesday Jun 18, 2024 by Dow Jones
Jun 11, 2024
Candel Therapeutics to Join Russell 3000(R) Index, from 8:00AM ET on Tuesday Jun 11, 2024 by Dow Jones
8:00AM ET on Tuesday Jun 11, 2024 by Dow Jones
Jun 3, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Candel Therapeutics Inc | 184.5M | -4.9x | --- |
Design Therapeutics Inc | 189.3M | -3.1x | --- |
Immutep Ltd | 284.8M | -7.7x | --- |
Acrivon Therapeutics Inc | 179.1M | -2.0x | --- |
Rani Therapeutics Holdings Inc | 191.6M | -3.0x | --- |
Pyxis Oncology Inc | 194.9M | -2.3x | --- |
Company Information
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.
Contact Information
- Headquarters
- 117 Kendrick Street,, Suite 450NEEDHAM, MA, United States 02494
- Phone
- 617-916-5445
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Paul Manning
- President, Chief Executive Officer, Director
- Paul Tak
- Interim Chief Financial Officer
- Charles Schoch
- Chief Scientific Officer
- Francesca Barone
- Vice President - Development Leader
- Christopher Matheny
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $184.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 29.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.29 |
Book Value | $0.44 |
P/E Ratio | -4.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
